Developer docs
API playgroundTry for free, no card

Search company profiles

Bod Science

Full company profile

uuid00sjhh7

Namestring
Bod Science
Legal namestring
Bod Science Pty Ltd
Websiteurl
bodscience.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Bod Science Pty Ltd is an Australian privately-held medicinal cannabis company headquartered in Sydney, New South Wales, founded in 2016. The company develops and supplies TGA-compliant pharmaceutical-grade cannabis-derived medicines, with its core commercial product being Bod MediCabilis, a 5% CBD full-spectrum oil (containing LINNEA 315CSE) supplied as a prescription-only medicine through the Therapeutic Goods Administration Special Access Scheme and Authorised Prescriber pathways. Bod operates a clinical R&D pipeline spanning novel CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, ECS317, ECS100, and Bod Es310) evaluated across insomnia, Motor Neuron Disease, Long Covid, anxiety, inflammation, and animal health indications, with multiple Phase I and Phase II trials in progress at institutions including University of Sydney, University of Technology Sydney, University of South Australia, the Woolcock Institute, and Gold Coast University Hospital. A peer-reviewed Phase I pharmacokinetic study of MediCabilis was published in the British Journal of Clinical Pharmacology, and Bod holds one of only six globally validated Novel Food Applications enabling CBD sales in the UK and EU.

Bod generates revenue through prescription product sales fulfilled via a pharmacy channel and through clinical trial and observational study services (including the BODOLOS observational study). Distribution occurs through a pharmacy fulfillment network and an integrated clinic channel featuring named cannabis-medicine specialists with TeleHealth services (Ananda Clinics, Australian Access Clinics, Cannabis Doctors Australia, Tetra Health), with exclusive global distribution handled by H&H Global. The company targets the Australian market as primary and the United Kingdom as a secondary market, participating in Project Twenty21, the UK's largest medical cannabis patient study. Bod also develops proprietary delivery technologies including a wafer format and a novel protein delivery system (Project Skin) for topical anti-aging applications, indicating diversification beyond oil-based CBD into adjacent delivery and consumer formats.

Short descriptiontext

Bod Science is an Australian medicinal cannabis company that develops and supplies TGA-compliant pharmaceutical-grade CBD products (Bod MediCabilis) and a clinical-stage pipeline of cannabinoid formulations, serving prescribing doctors, pharmacies, and patients with chronic conditions across Australia and the UK.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medicinal cannabis products, pharmaceutical grade CBD, cannabinoid clinical trials, TGA compliant cannabis, prescription cannabis therapeutics
Industry2 codes
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Medicinal Cannabis Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Prescription Medicinal Cannabis Products
TypeOthers
Description

Bod Science generates revenue through the sale of prescription-only medicinal cannabis products, primarily Bod MediCabilis. Pharmacies order directly from Bod once prescriptions and TGA approvals are received.

bodscience.com
2Clinical Trial Services
TypeProfessional Services
Description

Revenue from conducting clinical trials and observational studies (BODOLOS study) that generate real-world evidence on doctor prescribing habits and product efficacy, supporting regulatory registrations and commercial opportunities.

bodscience.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Bod MediCabilis
Description

Prescription-only medicinal cannabis product offered by Bod Science.

bodscience.com
+5 more records
Core offering1 text field

Bod Science supplies pharmaceutical-grade medicinal cannabis products — primarily Bod MediCabilis (5% CBD full-spectrum oil using LINNEA 315CSE™) — as prescription-only medicines through Australia's TGA Special Access Scheme (SAS) and Authorised Prescriber pathways. The company maintains a clinical R&D pipeline of CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, Bod ECS317, Bod ECS100, Bod Es310) targeting insomnia, Motor Neuron Disease, Long Covid, anxiety, and inflammation, alongside proprietary wafer-based cannabinoid delivery technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 50% increase in patients' self-reported health and ability to lead a normal life (Project Twenty21 findings for CBD in inflammation)
+3 more records
Product overview1 text field

Bod Science is an Australian medicinal cannabis company providing a portfolio of pharmaceutical-grade cannabis-derived products through regulated healthcare pathways. The core product is Bod MediCabilis (5% CBD full-spectrum oil), which is supplied as a prescription-only medicine. The company maintains an active clinical trial pipeline including Bod Bio Absorb (novel CBD), Bod ECS315 (CBD extract), Bod ECS100, Bod ECS317 (CBG), and Bod Es310 (CBN) for conditions such as insomnia, anxiety, inflammation, Motor Neuron Disease, and Long Covid. Bod also develops proprietary delivery technologies including wafer-based formats, and conducts research into novel proteins for topical skincare applications. Products are distributed through pharmacies, medical clinics, and telehealth services across Australia via TGA pathways.

Product and service8 records
1Bod MediCabilis
CategoryMedicinal cannabis pharmaceutical product
Description

Pharmaceutical-grade 5% CBD full-spectrum oil product (MediCabilis 5% CBD with LINNEA 315CSE) supplied as a prescription-only medicine through the TGA Special Access Scheme and Authorised Prescriber pathways. For Australian doctors prescribing to eligible patients and pharmacies dispensing prescriptions.

2Bod Bio Absorb (clinical trial compound)
CategoryCannabinoid R&D pipeline product
Description

Novel CBD compound in Bod's R&D pipeline being evaluated in a Phase II insomnia study for safety, tolerability, pharmacokinetics, and efficacy, with the goal of supporting future TGA registration for over-the-counter pharmacy sales.

3Bod ECS315 (clinical trial compound)
CategoryCannabinoid R&D pipeline product
Description

CBD extract evaluated across multiple clinical programmes including the Emerald Study (Phase II) for Motor Neuron Disease, Long Covid symptom studies, a Phase I pharmacokinetic trial, toxicology work, and the BODOLOS observational study of real-world prescribing habits.

4Bod Es310 — CBN Insomnia Study compound
CategoryCannabinoid R&D pipeline product
Description

CBN (cannabinol) formulation being evaluated in a Phase I CBN Insomnia Study for the treatment of primary insomnia, conducted in collaboration with the University of Sydney and The Woolcock Institute of Medical Research.

5Bod ECS317 and Bod ECS100 — Project Chang'e combination products
CategoryCannabinoid R&D pipeline product
Description

Cannabinoid formulations — Bod ECS317 (CBG) combined with Bod ECS100 and probiotics — evaluated under Project Chang'e for stress, anxiety, and inflammation in animals, with research output intended to support future human CBG and CBD product launches.

6Project Skin — novel protein delivery for anti-aging
CategoryTopical delivery R&D programme
Description

Novel protein-based topical delivery technology being evaluated for anti-aging efficacy through inhibition of free radical damage on skin.

7Innovation Wafer Delivery Technology
CategoryProprietary drug delivery technology
Description

Proprietary wafer-based delivery format for cannabis-based medicines; Phase 1 clinical study at Nucleus Network assessed safety, tolerability and pharmacokinetics and was published in the British Journal of Clinical Pharmacology.

8CAN-REST insomnia clinical study participation
CategoryClinical trial participation programme
Description

Patient recruitment programme for a clinical study using cannabinoid-based medications to evaluate a novel approach to insomnia relief. Aimed at Australian patients seeking non-standard treatment for primary insomnia.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive partnership agreement providing Bod with a leading distribution partner that has an established reputation, global brands and international market presence. This is a flagship partnership supporting Bod's global distribution strategy.

2Lambert Initiative (University of Sydney)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with the renowned Lambert Initiative for Cannabinoid Research at University of Sydney for ongoing development and definition of the future of medicinal cannabis.

bodscience.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with University of Technology Sydney for research and development of medicinal cannabis products and applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with University of South Australia for ongoing research of Bod full-spectrum product (50mg CBD/mL), providing valuable information for clinical practice and future research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for Emerald Study (Phase II) evaluating the use of CBD (Bod ECS315) in slowing progression of Motor Neuron Disease.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for Phase I CBN Insomnia Study evaluating CBN (Bod Es310) for treating primary insomnia.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Phase 1 clinical study assessing safety, tolerability and pharmacokinetics of MediCabilis conducted at Nucleus Network and published in British Journal of Clinical Pharmacology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian medicinal cannabis company supplying TGA-compliant pharmaceutical-grade cannabis products to Australian patients via prescription pathways. Highly comparable to Bod Science in product portfolio, regulatory approach, and pharmacy distribution model.

TypeDirect peer
Description

Australian-listed medicinal cannabis company focused on clinically validated cannabinoid formulations for insomnia, chronic pain, and other indications. Highly comparable clinical-trial-driven approach and prescription distribution model.

TypeDirect peer
Description

Australian medicinal cannabis cultivator and manufacturer supplying TGA-regulated cannabis medicines through similar prescription channels. Direct competitor to Bod in the Australian medicinal cannabis wholesale market with overlapping product formats.

4Lambert Initiative for Cannabinoid Research (University of Sydney)
TypeOthers
Description

Bod's R&D partner and Australia's leading academic center for medicinal cannabis research. While not a commercial competitor, it is highly relevant given its co-development role with Bod's ECS315 and broader pipeline, and as a source of competing clinical evidence.

TypeBroad incumbent
Description

Global specialty pharma company that acquired GW Pharmaceuticals, the originator of cannabinoid-based prescription medicines (Sativex, Epidiolex). Represents the gold standard for clinical-grade cannabis therapeutics and a long-term benchmark for Bod's clinical pipeline.

TypeDirect peer
Description

Australian medicinal cannabis manufacturer producing pharmaceutical-grade cannabis oils supplied via SAS and Authorised Prescriber pathways. Direct competitor to Bod MediCabilis with comparable product formats and clinical positioning.

7Medlab Clinical
TypeEmerging player
Description

Australian biotech developing cannabinoid-based medicines with clinical research focus. Comparable to Bod in therapeutic positioning, clinical evidence emphasis, and Australian TGA pathway approach.

8MGC Pharmaceuticals
TypeDirect peer
Description

Australia- and UK-based medicinal cannabis company with phytomedicine products sold through prescription and pharmacy channels. Direct competitor in both of Bod's core operating geographies with similar TGA/SAS positioning.

TypeDirect peer
Description

Australian pharmaceutical-grade medicinal cannabis company producing cannabinoid-based medicines for chronic conditions. Comparable in regulatory pathway, product positioning, and patient-targeting model to Bod Science.

10Tilray Brands
TypeBroad incumbent
Description

Large global cannabis company with a pharmaceutical-grade medicinal cannabis portfolio including products in Australian and European markets. Significant competitive pressure on Bod due to scale, capital, and broader product range.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bod Science

Medicinal Cannabis Pharmaceuticalsbodscience.com

Bod Science is an Australian medicinal cannabis company that develops and supplies TGA-compliant pharmaceutical-grade CBD products (Bod MediCabilis) and a clinical-stage pipeline of cannabinoid formulations, serving prescribing doctors, pharmacies, and patients with chronic conditions across Australia and the UK.

What Bod Science does

Bod Science Pty Ltd is an Australian privately-held medicinal cannabis company headquartered in Sydney, New South Wales, founded in 2016. The company develops and supplies TGA-compliant pharmaceutical-grade cannabis-derived medicines, with its core commercial product being Bod MediCabilis, a 5% CBD full-spectrum oil (containing LINNEA 315CSE) supplied as a prescription-only medicine through the Therapeutic Goods Administration Special Access Scheme and Authorised Prescriber pathways. Bod operates a clinical R&D pipeline spanning novel CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, ECS317, ECS100, and Bod Es310) evaluated across insomnia, Motor Neuron Disease, Long Covid, anxiety, inflammation, and animal health indications, with multiple Phase I and Phase II trials in progress at institutions including University of Sydney, University of Technology Sydney, University of South Australia, the Woolcock Institute, and Gold Coast University Hospital. A peer-reviewed Phase I pharmacokinetic study of MediCabilis was published in the British Journal of Clinical Pharmacology, and Bod holds one of only six globally validated Novel Food Applications enabling CBD sales in the UK and EU.

Bod generates revenue through prescription product sales fulfilled via a pharmacy channel and through clinical trial and observational study services (including the BODOLOS observational study). Distribution occurs through a pharmacy fulfillment network and an integrated clinic channel featuring named cannabis-medicine specialists with TeleHealth services (Ananda Clinics, Australian Access Clinics, Cannabis Doctors Australia, Tetra Health), with exclusive global distribution handled by H&H Global. The company targets the Australian market as primary and the United Kingdom as a secondary market, participating in Project Twenty21, the UK's largest medical cannabis patient study. Bod also develops proprietary delivery technologies including a wafer format and a novel protein delivery system (Project Skin) for topical anti-aging applications, indicating diversification beyond oil-based CBD into adjacent delivery and consumer formats.

Bod Science firmographics

Firmographics
Name
Bod Science
Legal name
Bod Science Pty Ltd
Website
https://bodscience.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Bod Science is an Australian medicinal cannabis company that develops and supplies TGA-compliant pharmaceutical-grade CBD products (Bod MediCabilis) and a clinical-stage pipeline of cannabinoid formulations, serving prescribing doctors, pharmacies, and patients with chronic conditions across Australia and the UK.
Ownership category
akta.pro rank

Bod Science industry classification

Industry
Product category
Medicinal Cannabis Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medicinal cannabis products
  • Pharmaceutical grade CBD
  • Cannabinoid clinical trials
  • TGA compliant cannabis
  • Prescription cannabis therapeutics

Where Bod Science is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Bod Science business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. Prescription Medicinal Cannabis Products: Bod Science generates revenue through the sale of prescription-only medicinal cannabis products, primarily Bod MediCabilis. Pharmacies order directly from Bod once prescriptions and TGA approvals are received.
  2. Clinical Trial Services: Revenue from conducting clinical trials and observational studies (BODOLOS study) that generate real-world evidence on doctor prescribing habits and product efficacy, supporting regulatory registrations and commercial opportunities.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Bod Science product offering

Product offering

Core offering

Bod Science supplies pharmaceutical-grade medicinal cannabis products — primarily Bod MediCabilis (5% CBD full-spectrum oil using LINNEA 315CSE™) — as prescription-only medicines through Australia's TGA Special Access Scheme (SAS) and Authorised Prescriber pathways. The company maintains a clinical R&D pipeline of CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, Bod ECS317, Bod ECS100, Bod Es310) targeting insomnia, Motor Neuron Disease, Long Covid, anxiety, and inflammation, alongside proprietary wafer-based cannabinoid delivery technology.

Product overview

Bod Science is an Australian medicinal cannabis company providing a portfolio of pharmaceutical-grade cannabis-derived products through regulated healthcare pathways. The core product is Bod MediCabilis (5% CBD full-spectrum oil), which is supplied as a prescription-only medicine. The company maintains an active clinical trial pipeline including Bod Bio Absorb (novel CBD), Bod ECS315 (CBD extract), Bod ECS100, Bod ECS317 (CBG), and Bod Es310 (CBN) for conditions such as insomnia, anxiety, inflammation, Motor Neuron Disease, and Long Covid. Bod also develops proprietary delivery technologies including wafer-based formats, and conducts research into novel proteins for topical skincare applications. Products are distributed through pharmacies, medical clinics, and telehealth services across Australia via TGA pathways.

Differentiator

Problem solved

Functional benefit

Brands

  • Bod MediCabilis: Prescription-only medicinal cannabis product offered by Bod Science.
  • Bod Bio Absorb
  • Bod ECS317
  • Bod ECS100
  • Bod ECS315
  • Bod ECS310

Products and services

  • Bod MediCabilis Pharmaceutical-grade 5% CBD full-spectrum oil product (MediCabilis 5% CBD with LINNEA 315CSE) supplied as a prescription-only medicine through the TGA Special Access Scheme and Authorised Prescriber pathways. For Australian doctors prescribing to eligible patients and pharmacies dispensing prescriptions.
  • Bod Bio Absorb (clinical trial compound) Novel CBD compound in Bod's R&D pipeline being evaluated in a Phase II insomnia study for safety, tolerability, pharmacokinetics, and efficacy, with the goal of supporting future TGA registration for over-the-counter pharmacy sales.
  • Bod ECS315 (clinical trial compound) CBD extract evaluated across multiple clinical programmes including the Emerald Study (Phase II) for Motor Neuron Disease, Long Covid symptom studies, a Phase I pharmacokinetic trial, toxicology work, and the BODOLOS observational study of real-world prescribing habits.
  • Bod Es310 — CBN Insomnia Study compound CBN (cannabinol) formulation being evaluated in a Phase I CBN Insomnia Study for the treatment of primary insomnia, conducted in collaboration with the University of Sydney and The Woolcock Institute of Medical Research.
  • Bod ECS317 and Bod ECS100 — Project Chang'e combination products Cannabinoid formulations — Bod ECS317 (CBG) combined with Bod ECS100 and probiotics — evaluated under Project Chang'e for stress, anxiety, and inflammation in animals, with research output intended to support future human CBG and CBD product launches.
  • Project Skin — novel protein delivery for anti-aging Novel protein-based topical delivery technology being evaluated for anti-aging efficacy through inhibition of free radical damage on skin.
  • Innovation Wafer Delivery Technology Proprietary wafer-based delivery format for cannabis-based medicines; Phase 1 clinical study at Nucleus Network assessed safety, tolerability and pharmacokinetics and was published in the British Journal of Clinical Pharmacology.
  • CAN-REST insomnia clinical study participation Patient recruitment programme for a clinical study using cannabinoid-based medications to evaluate a novel approach to insomnia relief. Aimed at Australian patients seeking non-standard treatment for primary insomnia.

Quantifiable outcome

  • 50% increase in patients' self-reported health and ability to lead a normal life (Project Twenty21 findings for CBD in inflammation)
  • +3 more outcomes

Companies that use Bod Science

Customer profile

Segments3 records

Ideal customer profiles3 records

Bod Science technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bod Science partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • H&H GlobalcoreChannel Partner/ Reseller/ DistributorExclusive partnership agreement providing Bod with a leading distribution partner that has an established reputation, global brands and international market presence. This is a flagship partnership supporting Bod's global distribution strategy.
  • Lambert Initiative (University of Sydney)coreStrategic or Co-development PartnerCollaboration with the renowned Lambert Initiative for Cannabinoid Research at University of Sydney for ongoing development and definition of the future of medicinal cannabis.
  • University of Technology SydneycoreStrategic or Co-development PartnerCollaboration with University of Technology Sydney for research and development of medicinal cannabis products and applications.
  • University of South AustraliacoreStrategic or Co-development PartnerPartnership with University of South Australia for ongoing research of Bod full-spectrum product (50mg CBD/mL), providing valuable information for clinical practice and future research.
  • Gold Coast University HospitalminorStrategic or Co-development PartnerCollaboration for Emerald Study (Phase II) evaluating the use of CBD (Bod ECS315) in slowing progression of Motor Neuron Disease.
  • University of Sydney and The Woolcock Institute of Medical ResearchminorStrategic or Co-development PartnerCollaboration for Phase I CBN Insomnia Study evaluating CBN (Bod Es310) for treating primary insomnia.
  • Nucleus NetworkminorStrategic or Co-development PartnerPhase 1 clinical study assessing safety, tolerability and pharmacokinetics of MediCabilis conducted at Nucleus Network and published in British Journal of Clinical Pharmacology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Bod Science competitors and assessment

Company assessment

Direct peers

  • Althea Group Holdings: Australian medicinal cannabis company supplying TGA-compliant pharmaceutical-grade cannabis products to Australian patients via prescription pathways. Highly comparable to Bod Science in product portfolio, regulatory approach, and pharmacy distribution model.
  • Zelira Therapeutics: Australian-listed medicinal cannabis company focused on clinically validated cannabinoid formulations for insomnia, chronic pain, and other indications. Highly comparable clinical-trial-driven approach and prescription distribution model.
  • Cann Group Limited: Australian medicinal cannabis cultivator and manufacturer supplying TGA-regulated cannabis medicines through similar prescription channels. Direct competitor to Bod in the Australian medicinal cannabis wholesale market with overlapping product formats.
  • Little Green Pharma: Australian medicinal cannabis manufacturer producing pharmaceutical-grade cannabis oils supplied via SAS and Authorised Prescriber pathways. Direct competitor to Bod MediCabilis with comparable product formats and clinical positioning.
  • MGC Pharmaceuticals: Australia- and UK-based medicinal cannabis company with phytomedicine products sold through prescription and pharmacy channels. Direct competitor in both of Bod's core operating geographies with similar TGA/SAS positioning.
  • AusCann Group Holdings: Australian pharmaceutical-grade medicinal cannabis company producing cannabinoid-based medicines for chronic conditions. Comparable in regulatory pathway, product positioning, and patient-targeting model to Bod Science.

Others

  • Lambert Initiative for Cannabinoid Research (University of Sydney): Bod's R&D partner and Australia's leading academic center for medicinal cannabis research. While not a commercial competitor, it is highly relevant given its co-development role with Bod's ECS315 and broader pipeline, and as a source of competing clinical evidence.

Broad incumbents

  • Jazz Pharmaceuticals (GW Pharmaceuticals): Global specialty pharma company that acquired GW Pharmaceuticals, the originator of cannabinoid-based prescription medicines (Sativex, Epidiolex). Represents the gold standard for clinical-grade cannabis therapeutics and a long-term benchmark for Bod's clinical pipeline.
  • Tilray Brands: Large global cannabis company with a pharmaceutical-grade medicinal cannabis portfolio including products in Australian and European markets. Significant competitive pressure on Bod due to scale, capital, and broader product range.

Emerging players

  • Medlab Clinical: Australian biotech developing cannabinoid-based medicines with clinical research focus. Comparable to Bod in therapeutic positioning, clinical evidence emphasis, and Australian TGA pathway approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Bod Science social profiles

Digital presence

Bod Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bod Science leadership team

Management profile

Number of profiles

Bod Science funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bod Science M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bod Science

What does Bod Science do?

Bod Science supplies pharmaceutical-grade medicinal cannabis products — primarily Bod MediCabilis (5% CBD full-spectrum oil using LINNEA 315CSE™) — as prescription-only medicines through Australia's TGA Special Access Scheme (SAS) and Authorised Prescriber pathways. The company maintains a clinical R&D pipeline of CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, Bod ECS317, Bod ECS100, Bod Es310) targeting insomnia, Motor Neuron Disease, Long Covid, anxiety, and inflammation, alongside proprietary wafer-based cannabinoid delivery technology.

Is Bod Science a public or private company?

Bod Science is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bod Science founded?

Bod Science was founded in 2016. It employs 1 to 10 people.

Where is Bod Science based?

Bod Science is headquartered in Sydney, Australia, in the Oceania region.

How does Bod Science make money?

Two revenue lines are on record. Prescription Medicinal Cannabis Products are the primary driver. The others are clinical Trial Services.

Who are Bod Science's main competitors?

Direct peers on record are Althea Group Holdings, Zelira Therapeutics, Cann Group Limited, Little Green Pharma, MGC Pharmaceuticals and AusCann Group Holdings. Lambert Initiative for Cannabinoid Research (University of Sydney) is listed as an others. Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals) and Tilray Brands. Medlab Clinical is listed as an emerging player.

Does Bod Science have an API?

No public API is recorded for Bod Science.

What industry is Bod Science in?

Bod Science's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAHAC, CBD/Hemp Wellness & Supplements Retail, with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals